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DOI 10.1016/j.ccr.2010.04.011SUMMARYUptake of the anticancer drug cisplatin is mediated by the copper transporter CTR1 in cultured cells. Here
we show in human ovarian tumors that low levels of Ctr1 mRNA are associated with poor clinical response
to platinum-based therapy. Using a mouse model of human cervical cancer, we demonstrate that combined
treatment with a copper chelator and cisplatin increases cisplatin-DNA adduct levels in cancerous but not in
normal tissues, impairs angiogenesis, and improves therapeutic efficacy. The copper chelator also enhances
the killing of cultured human cervical and ovarian cancer cells with cisplatin. Our results identify the copper
transporter as a therapeutic target, which can be manipulated with copper chelating drugs to selectively
enhance the benefits of platinum-containing chemotherapeutic agents.INTRODUCTION
Cisplatin is widely used for the treatment of solid tumors. It is
a component of first-line treatment for testicular, ovarian,
cervical, endometrial, bladder, head and neck, lung, and gastro-
esophageal cancers (Hussain et al., 2008; Omura, 2008; Gal-
lagher et al., 2008; Yang et al., 2009; Lustberg and Edelman,
2007; Fischer and Arcaro, 2008; Cen and Ajani, 2007). It is also
used as a second- or third-line treatment for prostate and
pancreatic cancers, metastatic cancer of the breast, and for
melanoma and gliomas (Carrick et al., 2004; Oh et al., 2007;
Saif and Kim, 2007; Atallah and Flaherty, 2005; Glioma Meta-
Analysis Trialists Group, 2002). The dosage and efficacy of
cisplatin, however, are limited by its side effects, the most prom-
inent being nephrotoxicity (Pabla and Dong, 2008).
Cisplatin exerts its cytotoxic effect by forming an intrastrand
crosslink on DNA (Jamieson and Lippard, 1999). Studies of
cisplatin-resistant cell lines have revealed drug uptake as a crit-
ical step that governs cisplatin sensitivity in vitro (Hall et al.,
2008). A yeast genetic screen for cisplatin-resistant mutants
identified the copper transporter CTR1 as a major mediator ofSignificance
Inefficient drug delivery and attendant toxicity represent imped
tomitigate these limitations for the anticancer drug cisplatin, wh
show that therapeutic preconditioning with a copper chelator
affecting normal organs in a mouse model of cervical cancer. C
with the efficacy of platinum-based chemotherapy. These re
tumors with copper chelators so as to improve the benefits a
therapy.
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Upon exposure to excess copper, Ctr1 protein undergoes endo-
cytosis and degradation (Ooi et al., 1996; Petris et al., 2003).
Pretreatment of cells with high copper results in decreased
cisplatin uptake and increased resistance to this drug in
a CTR1-dependent manner (Ishida et al., 2002), whereas
chelating copper with bathocuprione disulphonate has opposite
effects (S.I. and I. Herskowitz, unpublished data). These results
demonstrated that cisplatin uptake can be modulated by copper
levels in vitro through Ctr1p.
In this study, we examined the in vivo roles of Ctr1 and copper
in cisplatin uptake and response using a mouse model of human
cervical cancer. Cervical cancer is the second most common
cause of cancer-related death among women worldwide.
Cisplatin has been one of the most active single agents and
a component of combined-agent chemotherapy regimens for
patients with advanced cervical cancer. The response rates for
cisplatin alone range from 13%–19%, with an overall survival
time of 6–9 months; the current combined-agent therapy is
only modestly better, with response rates of 27%–36%, with
overall survival of 8–10months (Tao et al., 2008). Cervical canceriments to successful chemotherapy. We present a strategy
ose uptake ismediated by the copper transporter CTR1.We
enhances cisplatin uptake and killing of cancer cells without
oncordantly, Ctr1 levels in human ovarian tumors correlate
sults encourage clinical trials aimed to upregulate CTR1 in
nd potentially expand the scope of platinum-based chemo-
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Modulating Copper Improves Cisplatin Efficacyis caused by integration and persistent expression of genes of
human papilloma viruses (HPV), of which HPV type 16 is
detected in a majority of cases of invasive carcinoma (Castell-
sague, 2008). In the mouse model of cervical carcinoma,
K14-HPV16/E2, the HPV16-encoded oncogenes are under the
control of the keratin 14 promoter, resulting in targeted onco-
gene expression in keratin 14-positive squamous epithelial cells,
a natural host-cell target for HPV infection in humans (Arbeit
et al., 1996). When the estrogen levels of K14-HPV16 females
are maintained at a level near their natural peak during estrus
with time-released implants of 17b-estradiol (estrogen, E2), the
female mice (referred to as HPV16/E2 mice hereafter) develop
progressive cervical intraepithelial neoplasia (CIN) lesions at
the transformation zone, the site implicated in the genesis of
human cervical cancer (Elson et al., 2000). By 6 months of age,
these CIN lesions progress to invasive squamous cell carcinoma
in 90% of the animals. Both male and female K14-HPV16 mice
also develop dysplasia of the skin, and skin tumors arise later,
with 50% penetrance by 12 months of age (Coussens et al.,
1996).
Using this mousemodel of human cervical carcinoma, HPV16/
E2, we ask whether a copper chelator selectively increases
cisplatin uptake and killing of tumor cells without affecting
normal organs, thereby increasing the antitumoral efficacy of
cisplatin. We also analyze human ovarian tumors for expression
of the copper transporter Ctr1 to evaluate its association with
clinical response to platinum drugs, and assess the capability
of the copper chelator to enhance killing of human ovarian and
cervical cancer cell lines with cisplatin.
RESULTS
Human Ctr1 mRNA Levels in Tumors Are Associated
with Clinical Response to Platinum-Based
Chemotherapy in Ovarian Cancer
Previous studies using mouse embryonic fibroblasts (MEFs)
deleted for the mouse Ctr1 gene demonstrated a correlation
between Ctr1 gene dosage and cisplatin sensitivity in vitro: cells
that are heterozygous for a knockout allele of mouse Ctr1 were
more resistant than wild-type cells to cisplatin, and homozygous
mutant cells were more resistant than heterozygous cells
(Ishida et al., 2002). These findings raised the hypothesis that
Ctr1mRNA levels correlate with and thus explain differential clin-
ical responses to platinum drugs. To address this possibility, we
analyzed tumor specimens and the clinical course of 15 ovarian
cancer patients. The standard treatment for advanced ovarian
cancer is primary cytoreductive surgery followed by chemo-
therapy that includes a platinum drug. Resistance to platinum-
based chemotherapy remains a primary factor in disease
recurrence. Figure 1A lists the baseline characteristics of the
15 patients, all with advanced-stage (stage III or IV), serous
epithelial ovarian carcinoma. The tumors were of mixed grade
(Figure 1A). Following optimal cytoreductive surgery resulting
in residual tumors of 1 cm or less in diameter, the patients
received regimens containing either cisplatin or carboplatin,
and paclitaxel. Prior clinical studies have revealed equal efficacy
for the two platinum compounds (Ozols et al., 2003; du Bois
et al., 2003). The mechanisms of resistance are thought to be
similar for the two drugs, which share the same putative trans-porter CTR1 (Holzer et al., 2006). Of the 15 patients, 9 proved
to be sensitive to platinum-based therapy (no evidence of recur-
rence within 6 months after completion of primary therapy),
whereas the remaining 6 were refractory or resistant (progres-
sion or recurrence within 6 months of completion of therapy,
as indicated by an increase in CA-125 levels, or by CT, ultraso-
nography, or second-look laparoscopy) (see Figure S1A
available online). RNA was prepared from these patients’ tumor
samples, and Ctr1 mRNA levels were measured by quantitative
reverse-transcriptase polymerase chain reaction (RT-PCR).
The mean relative Ctr1 mRNA level was substantially higher in
platinum-sensitive patients than in refractory/resistant patients
(43% versus 18% of internal control gene expression, p =
0.016) (Figure 1B). Expression levels of the internal control
gene human GUS, which encodes b-glucuronidase, were equiv-
alent between the two patient groups (average ± standard
deviation [SD] Ct in sensitive group was 28.2 ± 0.8 versus
28.1 ± 1.3 in resistant/refractory group, p = 0.69) (Figure S1B).
These findings suggest that Ctr1 expression in ovarian tumors
is associated with platinum drug response.
In order to validate these findings in an independent data set,
we used clinical and array-based expression data from The
Cancer Genome Atlas (TCGA) that are deposited at the Data
Coordinating Center for public access (http://cancergenome.
nih.gov/). We defined a subset of 91 patients with stage III or
IV serous epithelial ovarian cancer who had undergone a cytore-
ductive surgery followed by adjuvant chemotherapy consisting
of a platinum drug and a taxane (http://tcga-data.nci.nih.gov/
tcga/homepage.htm) (Figure 1C). Results for Ctr1 expression
were extracted from expression data that were produced
using Affymetrix HT Human Genome U133A Array Plate Set
(HT_HG-U133A) (http://tcga-data.nci.nih.gov/tcga/dataAccess
Matrix.htm). The patients were divided into two groups by the
median Ctr1 expression value, resulting in 45 ‘‘high Ctr1’’ (above
median) and 46 ‘‘low Ctr1’’ (belowmedian) patients (Figure S1C).
High expression of Ctr1was associated with increased disease-
free survival (Figure 1D; log-rank statistic 8.67, hazard ratio 0.53,
p = 0.003), supporting our hypothesis that Ctr1 levels are
prognostic of treatment outcome. These findings suggest that
mRNA levels of the human copper transporter Ctr1 in tumors
are clinically relevant to the efficacy of platinum therapy.
Ctr1 mRNA Levels Correlate with Cisplatin Adduct
Levels in Mouse Tissues
To address the in vivo role of CTR1 in cisplatin uptake, we exam-
ined the levels ofCtr1mRNAand cisplatin-inducedDNAadducts
in various tissues of HPV16/E2, the mouse model of human
cervical cancer. Overall, the levels of cisplatin adducts corre-
lated with Ctr1 mRNA in most organs tested—skin, lung, liver,
pancreas, and uterus (Figure 2). Kidney contained the highest
amount of cisplatin adducts andCtr1mRNA, which is interesting
in light of the prevalence of nephrotoxicity among cisplatin-
treated patients. The colon contained fewer adducts relative to
Ctr1mRNA levels. In the duodenum and intestine, CTR1 protein
is localized to the apical surface facing the intestinal lumen and in
intracellular compartments (Nose et al., 2006; Kuo et al., 2006).
It is possible that such localized CTR1 in the digestive tract is
not involved in the uptake of cisplatin, which is administered
intravenously to patients, and in this experiment was suppliedCancer Cell 17, 574–583, June 15, 2010 ª2010 Elsevier Inc. 575
Figure 1. Low Levels of Ctr1 mRNA in
Ovarian Tumors Are Associated with Poor
Clinical Outcome
(A) Baseline characteristics of the 15 patients with
advanced-stage epithelial ovarian carcinoma,
whose tumors were analyzed for relative expres-
sion of the Ctr1 copper transporter.
(B) Tumor Ctr1 mRNA levels in platinum sensitive
and refractory/resistant ovarian cancer patients.
Bars represent mean values. Ctr1 mRNA levels
are expressed as a percentage relative to the
internal control of human GUS mRNA.
(C) Characteristics of 91 ovarian cancer patients
from The Cancer Genome Atlas study.
(D) Kaplan-Meier estimate of disease-free survival
for 91 advanced-stage ovarian cancer patients
according toCtr1 expression levels. Patientswhose
tumors expressedCtr1mRNA at levels higher than
the median value were classified as ‘‘High Ctr1’’
(red; 45 patients); the remaining patients were
labeled ‘‘Low Ctr1’’ (blue; 46 patients). The vertical
hash marks (at 7 and 10 months, High Ctr1) repre-
sent censored patients who were disease-free at
the last follow-up time indicated. See also
Figure S1.
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Modulating Copper Improves Cisplatin Efficacyintraperitoneally. Notably, the cancerous HPV16/E2 cervix
contained more adducts relative to Ctr1 mRNA levels. Expres-
sion in the cervix of the internal control genemouse L19, to which
Ctr1 mRNA was normalized, was equivalent to that of otherFigure 2. Levels of Ctr1 mRNA and Cisplatin Adducts in Various
Organs of the HPV16/E2 Female Mice
Organs were harvested from three 6-month-old HPV16/E2 females and Ctr1
mRNA levels were determined by quantitative RT-PCR (hatched bars). Mouse
L19mRNA levels were used as internal controls. For measurement of cisplatin
adducts, genomic DNA was purified from each organ (n = 8) 2 hr after 6 mg/kg
cisplatin was injected. Platinum was measured by ICP-MS and normalized to
the amount of DNA (solid bars). Error bars represent the standard error of the
mean. See also Figure S2.
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the cervix) (Figure S2A), indicating that the observed low levels
ofCtr1mRNA in the cervix is not a result of higher internal control
gene expression in the tumors. Despite the low Ctr1 mRNA
levels, CTR1 protein was substantially expressed in the can-
cerous cervix (Figure 3D), suggesting increased protein syn-
thesis and/or reduced protein turnover in this neoplastic tissue.
We also measured mRNA levels of the copper exporters,
ATP7A and ATP7B, which are involved in exporting cisplatin
in vitro (Komatsu et al., 2000; Samimi et al., 2004). Consistent
with prior reports (Bull et al., 1993; Tanzi et al., 1993), ATP7B
was primarily expressed in the liver (Figure S2B). We were able
to detect ATP7A mRNA in all the tissues tested, but did not
observe an inverse correlation between ATP7A mRNA levels
and tissue platinum levels, further supporting our proposition
that the copper transporter Ctr1 is the major determinant for
cisplatin accumulation in vivo as well.
The Copper Chelator Tetrathiomolybdate
Increases Cisplatin Adduct Levels
in Tumors but Not Normal Organs
Having observed an in vivo correlation between levels of the
copper transporter Ctr1 and cisplatin adducts in the majority of
tissues examined, we next asked whether reducing systemic
copper could result in increased cisplatin adducts in tumors.
We treated HPV16/E2 mice with the copper chelator tetrathio-
molybdate (TM), which is currently granted orphan designation
in the United States and Europe for the treatment of Wilson’s
disease, an autosomal recessive disorder characterized by
excess copper deposition in various organs. TM reduces bio-
available copper levels, primarily by forming a tripartite complex
with ingested copper and protein, preventing the absorption of
Figure 3. The Copper Chelator Tetrathiomolybdate Enhances Cisplatin Uptake into the Cervix of HPV16/E2 Mice
(A) Plasma copper levels in six-month-old HPV16/E2 females after a 3 week daily treatment with 1 mg tetrathiomolybdate (TM). Bars represent mean values.
(B) Cisplatin adduct levels in the cervix, skin, and kidney of six-month-old HPV16/E2 females (n = 12) and wild-type females (n = 5) that received either the
three-week TM treatment (solid bars) or no treatment (hatched bars). 6 mg/kg cisplatin was injected two hours before organs were harvested. Adduct levels
were determined as in Figure 2. Error bars represent the standard error of the mean.
(C) CTR1 immunohistochemistry reveals positive cells (green) in tumors (T) of the 6-month-old HPV16/E2 cervix (right panel) but not in the epithelium (E) of the
wild-type cervix (left panel). DAPI staining is shown in blue. The panels shown are representative images of 12 fields in three tissue sections per mouse collected
from three mice. Scale bars represent 100 mm.
(D) Tissue CTR1 protein levels are elevated in the neoplastic cervix, but unchanged in the context of TM treatment. Wild-type and HPV16/E2 mice were either
treated with 1 mg TM daily for 3 weeks prior to being sacrificed at 6 months of age, or did not receive such treatment. A total of 5 mg membrane extracts
from tissues was pooled from three mice and applied on each well.
(E) CTR1 protein (green) is predominantly localized in intracellular compartments in cervical carcinoma cells, and is unchanged by TM treatment. HPV16/E2 mice
were either treated with 1 mg TM daily for 3 weeks prior to being sacrificed at 6 months of age, or did not receive such treatment. Tissue sections were
immunostained with anti-CTR1 (green). Nuclei are stained with DAPI (blue). The images were collected using a 20x objective lens on a fluorescent microscope,
and are representative of > 500 cells in 12 sections from six tumors. Scale bars represent 5 mm.
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mined the maximally tolerated daily dose of TM for the HPV16/
E2 female mice to be 1 mg (data not shown). When the mice
are subjected to this daily dose of TM, plasma copper levels start
decreasing after 3 days, and reach a plateau after 2 weeks. We
did not observe any side effects during 3weeks of daily TM treat-
ment, at which point the plasma copper levels had decreased by
23% (Figure 3A). This TM dosage resulted in a 2.7-fold increasein cisplatin adduct levels in the cancerous cervix of the HPV16/E2
mice (7.2 mg Pt/ g DNA in control versus 19.8 mg Pt/ g DNA in
TM-treated mice, p = 0.02), but not in the wild-type cervix
(Figure 3B). Such a difference in the number of adducts is
considered significant because it can result in a 1000-fold differ-
ential in cell viability in vitro (Hall et al., 2008). Notably, this TM
regimen did not increase adducts in the kidney (Figure 3B),
which is the major organ affected by cisplatin toxicity, nor inCancer Cell 17, 574–583, June 15, 2010 ª2010 Elsevier Inc. 577
Figure 4. Preclinical Trials Assessing Therapeutic Effects of the Copper Chelator Tetrathiomolybdate in Combination with Cisplatin on De
Novo Cervical Carcinomas
(A) Schematic diagrams of each therapeutic arm. Cohorts of 14 female HPV16/E2 mice were subjected either to a 3 week oral administration of 1 mg tetrathio-
molybdate (TM) daily starting at 5 months of age, or to a single intraperitoneal injection of 6 mg/kg cisplatin at 5.75 months of age, or to both. All the mice were
sacrificed at 6 months of age.
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Modulating Copper Improves Cisplatin Efficacyother noncancerous organs of the mice. Interestingly, in the
absence of TM treatment, the kidneys of HPV16/E2 mice accu-
mulated 50% more platinum adducts than those of wild-type
mice (Figure 3B). This increase in the adduct level in the kidneys
of HPV16/E2 mice may be due to renal failure from urinary tract
obstruction, which is not uncommon both in cervical cancer
patients and in this mouse model. TM treatment also produced
a marginal 1.4-fold increase in the adduct level in the dysplastic
skin of the HPV16/E2 mice (2.8 mg Pt/ g DNA in control versus
3.9 mg Pt/g DNA in TM-treated mice, p = 0.03), but not in the
skin of wild-type mice, suggesting that neoplastic tissues may
become more sensitive to changes in copper levels. Notably,
we found that CTR1 protein is highly expressed in tumors of
the HPV16/E2 cervix but not in the epithelium of the wild-type
cervix, the origin of cervical carcinoma (Figure 3C). We were,
however, unable to detect any change in Ctr1 mRNA (data not
shown) or protein levels (Figure 3D) in response to TM treatment
in the neoplastic HPV16/E2 cervix or in normal tissues. In tumor
cells of the HPV16/E2 cervix, CTR1 protein was predominantly
localized in intracellular compartments; CTR1 remained intracel-
lular in TM-treated HPV16/E2 cervix (Figure 3E). It is possible that
the modest change in systemic copper (23% reduction) by TM
(Figure 3A) is not sufficient to cause measurable changes in
the levels of CTR1 protein, which is already high in these tumors,
or in its localization. However, TM treatment resulted in in-
creased cisplatin uptake in the HPV16/E2 cervix (Figure 3B),
demonstrating that even a small reduction in systemic copper
levels can increase the transport activity of CTR1 in tumors.
These data indicate that expression of the copper transporter
CTR1 is upregulated in neoplastic tissues compared to cognate
normal tissues, and that its transport activity could be further
elevated selectively in tumors by reducing systemic copper.The Copper Chelator Tetrathiomolybdate Enhances
Cisplatin Efficacy
For assessment of possible therapeutic benefits of using TM to
enhance the uptake and consequent cytotoxicity of cisplatin in
tumors, cohorts of 14 female HPV16/E2 mice were subjected
either to a 3 week regimen of oral 1 mg TM daily starting at
22 weeks of age, or to a single intraperitoneal injection of 6 mg/
kg cisplatin at 25 weeks of age, or to both (Figure 4A). At 22
weeks, all HPV16/E2 females have high-grade dysplasias (CIN
2/3), and about half have invasive cervical carcinomas. Animals
from all treatment arms were sacrificed at 26 weeks of age,(B) Tumor volumes in the cervix of 6-month-old HPV16/E2 mice from each trea
HPV16/E2 mice were analyzed as described in Experimental Procedures. Error b
(C) Representative H&E-stained cervices from each treatment arm, with the treat
the right. Themagnification is scaled by a bar below each panel indicating 50 mm. I
contain large keratinized cells with hyperchromatic nuclei. In the cisplatin-treated
keratinized, with enlarged, bizarre-shaped nuclei. In the TM-treated cervix (botto
infiltrates. The cervix treated with both TM and cisplatin (bottom right) shows histo
enlarged nuclei, necrotic centers, and inflammatory cell infiltrates. The panels sho
of 14 HPV16/E2 mice.
(D and E) Vascular density of tumors after treatment. 15 tumor sections from fi
Meca-32, followed by FITC-conjugated secondary antibody to visualize tumor e
and vascular density was determined using the Metamorph Angiogenesis Tube
with Meca-32-positive tube structures (E). Error bars represent the standard erro
of control and TM-treated HPV16/E2 mice are shown in (D). Nuclei are stained wwhen 90% have cervical carcinomas. Tumor volumes were
calculated bymeasuring tumor areas on serial sections. Cisplatin
treatment reduced tumor volumes to 55% of untreated cervix
(2.7 mm3 in control versus 1.5 mm3 with cisplatin, p = 0.01) (Fig-
ure 4B). In the cisplatin-treated cervix, cells had more abundant
cytoplasm that appeared keratinized (Figure 4C). Nuclei were
enlarged and bizarre in shape, characteristic features of human
cervical cancer treatedwith radiation (Robboy et al., 2002),which
causes DNA damage. TM alone also modestly decreased tumor
volumes in the cervix, to 65% of controls (2.7 mm3 in control
versus 1.7 mm3 with TM, p = 0.04) (Figure 4B). In the TM-treated
cervix, the center of a tumor mass was necrotic and filled with
inflammatory cell infiltrates (Figure 4C). The percentage of area
covered with meca-32-positive endothelial cells in the TM-
treated tumors was 2.6-fold less compared with those from
untreated mice (Figures 4D and 4E), consistent with prior obser-
vations that TM is antiangiogenic (Brewer and Merajver, 2002).
When cisplatin was combined with the TM treatment, tumor
volume decreased to 19%of untreated cervix (2.7mm3 in control
versus 0.5 mm3 with TM and cisplatin, p < 0.0001) (Figure 4B).
Microscopically, the cervical carcinoma from the combination
arm showed histologic features of the effects seen with both
cisplatin and TM monotherapies: enlarged nuclei, necrotic
centers, inflammatory cell infiltrates, and reduced vascularity
(Figures 4C and 4D). These results demonstrate that TM
enhances efficacy of cisplatin synergistically.The Copper Chelator Tetrathiomolybdate Increases
Cisplatin Sensitivity of Cancer Cells
Seeking to separate the antiangiogenic effect of TM on tumor
vasculature from its effect on tumor cell uptake of cisplatin, we
asked whether TM treatment increases cisplatin sensitivity and
uptake in cultures of SiHa cells, which are derived from an
HPV16-positive human cervical carcinoma (Friedl et al., 1970).
Plasma TM levels in the HPV16/E2 females range from 150 mM
to 4 mM, over the period from 3 to 24 hr after oral administration
of 1 mg TM, respectively (data not shown). We determined that
24 hr incubation with up to 10 mM TM does not inhibit prolifera-
tion of SiHa cells (Figure 5A). When SiHa cells were incubated
with 10 mM TM for 24 hr and then subjected to a 2 hr cisplatin
treatment, we observed a 2-fold increase in cisplatin sensitivity
and a 45% increase in cisplatin accumulation inside TM-treated
cells compared to cells that were not preincubated with TM
(Figures 5B and 5C). We also assessed effectiveness of thetment arm. Approximately 30 sections per mouse from cohorts of 14 female
ars represent the standard error of the mean.
ment indicated below each panel. Cells are shown at a higher magnification on
n the nontreated cancerous cervix (top left), invasive squamous cell carcinomas
cervix (top right), the cancer cells have more abundant cytoplasm that appears
m left), the center of a tumor mass is necrotic and filled with inflammatory cell
logical features of the effects seen with both cisplatin and TMmonotherapies:
wn are representative of four fields in 30 tissue sections collected from cohorts
ve mice per treatment arm were stained with a pan-endothelial cell antibody
ndothelial cells. Images were collected from five to seven fields per section,
Formation program. Data are expressed as the percentage of area covered
r of the mean. Representative images of Meca-32 (green) staining in the cervix
ith DAPI (blue). Scale bars represent 50 mm.
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Figure 5. Effects of the Copper Chelator Tetrathiomolybdate (TM) on Cisplatin Sensitivity in Cultured Mammalian Cells
(A) Effect of TM on cell proliferation in human cervical carcinoma cells. SiHa cells were plated in triplicates and treated with 0, 1, 10, or 100 mM TM for 24 hr.
Numbers of cells before and after the treatment are shown. Error bars represent the standard error of the mean.
(B and C) Effect of TM on cisplatin sensitivity and accumulation in human cervical carcinoma cells. SiHa cells were plated in triplicates and either pretreated with
10 mM TM or mock treated for 24 hr before a 2 hr incubation with cisplatin. For cell survival (B), data are expressed as percentage of viable cells compared with
control cultures not exposed to cisplatin. For determining cisplatin accumulation (C), cells were lysed and, after a centrifugation, the supernatant was used to
determine the platinum content and protein concentration. Cellular platinum readings were normalized to protein concentration. Mean values of the triplicates
are shown. Error bars represent the standard error of the mean.
(D) TM increasescisplatin sensitivity in humanovarian cancer cells.Cellswere plated in triplicates and eitherpretreatedwith 10mMTMormock treated for 6 hr (A2780),
12 hr (SKOV3), or 24 hr (OVCA4) before cisplatin treatment. Data are expressed as percentage of viable cells comparedwith control cultures not exposed to cisplatin.
(E) TM increases cisplatin sensitivity in a Ctr1-dependent manner. Isogenic mouse embryonic fibroblasts that are either wild-type or homozygous for a knockout
allele of Ctr1were either pretreated with 10 mMTM or mock treated for 24 hr before a 2 hr incubation with cisplatin. The percentage of viable cells compared with
control cultures not exposed to cisplatin is shown.
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ovarian cancer cell lines derived from patients’ tumors, A2780,
SKOV3, and OVCA4 (Eva et al., 1982; Fogh and Trempe,
1975). These cells had different growth properties: the doubling
time was 16 hr for A2780, 24 hr for SKOV3, and 36 hr for OVCA4
(data not shown). We determined that incubation of these cells
with 10 mM TM did not have an antiproliferative effect for up to
6 hr in A2780, 12 hr in SKOV3, and 24 hr for OVCA4 (data not
shown). When these cells were subsequently treated with
cisplatin, they exhibited 1.8- to 2.2-fold increased sensitivity
compared with cells that were not preincubated with TM
(Figure 5D), demonstrating that TM can increase cisplatin sensi-
tivity of ovarian cancer cells as well. To establish that the effects
of TM on enhancing cisplatin-mediated killing were dependent
on Ctr1, we compared isogenic MEFs that were either wild-
type or deleted for the Ctr1 gene (Lee et al., 2002). The ability
of TM to increase cisplatin killing proved to be dependent on
Ctr1: in wild-type MEFs, the percentage of cells that survived
a 2 hr treatment with 1 mM cisplatin was reduced to 0.16% in
cultures pretreated with TM, as compared with 1% in control
cultures (Figure 5E). In contrast, the percentage of cells surviving
cisplatin treatment was not affected by TM treatment in Ctr1 null
MEFs (Figure 5D). These results further support the role of the
copper chelator TM and the copper transporter CTR1 in
enhancing cisplatin uptake and killing of cancer cells.
DISCUSSION
Our studies in a mouse model of HPV16-induced cervical carci-
noma demonstrate that the copper chelator tetrathiomolybdate
has a synergistic antitumor effect when combined with cisplatin
treatment, by increasing uptake of cisplatin into tumors but not
normal tissues while concomitantly inhibiting tumor angiogen-
esis. We show that cisplatin adduct levels in various mouse
organs correlate with mRNA levels of Ctr1, supporting its
in vivo involvement in cisplatin uptake. Pretreatment of cultured
human cervical and ovarian cancer cells with TM resulted in
increased cisplatin sensitivity, encouraging applicability to
human cancers. TM-enhanced cisplatin killing was dependent
on Ctr1 because mouse cells deleted for the Ctr1 gene were
not sensitized to cisplatin by TM, in comparison to isogenic cells
with wild-type Ctr1. Notably, low levels of Ctr1 mRNA in human
ovarian tumors are associated with decreased disease-free
survival after platinum-based therapy in patients, suggesting
that Ctr1 may serve as a clinical predictor of response to plat-
inum agents.
Previous genetic experiments with yeast and mouse cells
demonstrated that the copper transporter Ctr1 is a major
determinant of cisplatin uptake and sensitivity, which could be
modulated by copper levels. These in vitro results suggested
a strategy to increase cisplatin uptake, but a challenge was to
find a clinically feasible method to do so selectively in tumors,
without affecting normal organs to avoid untoward toxicities of
cisplatin. Surprisingly, we were able to achieve this goal by
reducing systemic copper levels with a copper chelator in
a mouse model of cervical cancer. We do not fully understand
the mechanism by which reduced systemic copper leads to
increased cisplatin uptake only in tumors. Copper is essential
for a variety of key cellular processes such as respiration, freeradical detoxification, and iron uptake (Kim et al., 2008). Cancer
cells may have a greater demand for copper than normal cells
for proliferation and survival. Indeed, the copper transporter
CTR1 was more highly expressed in cervical carcinoma of the
HPV16/E2 mice than in the wild-type cervix. Concordant with
our observation is a recent demonstration using microbeam
synchrotron X-ray fluorescence, showing that copper is
concentrated in tumor regions of tissue specimens obtained
from invasive ductal carcinoma of the breast (Farquharson
et al., 2008).
Although pretreatment of mice with the copper chelator TM
resulted in increased cisplatin sensitivity and adducts in tumors,
wewere unable to detect any increase in the levels ofCtr1mRNA
or protein. In vitro, elevated extracellular copper causes endocy-
tosis and degradation of human CTR1 protein (Petris et al.,
2003).We did not, however, observe any change in CTR1 protein
localization in the TM-treated cervix of HPV16/E2 mice. It is
possible that copper starvation enhances cisplatin transport
activity by changing the conformation of CTR1, allowing more
cisplatin to be transported into cells. Exogenous copper has
been shown to induce structural rearrangements in yeast Ctr1p
(Sinani et al., 2007). Further biochemical studies will be required
to elucidate the mechanism by which copper chelation causes
increased cisplatin uptake.
Drug-induced toxicity is a common cause for discontinuation
or dose reduction of chemotherapeutic drugs during cancer
treatment. Cancers that are deemed ‘‘resistant’’ to a chemother-
apeutic drug fail to respond to the dosage tolerated by patients
without untoward side effects. These ‘‘resistant’’ cancers might
in principle still respond to a higher dosage if toxicities were
not manifest. By reducing bioavailable copper with the copper
chelator TM, we were able to increase cisplatin activity in highly
metabolic tumors while comparatively sparing normal organs.
TM was developed for the treatment of patients with Wilson’s
disease, an autosomal recessive disorder of copper transport
that results in excessive accumulation of copper and toxicity.
Phase II and III trials withWilson’s disease patients have demon-
strated that TM is a fast-acting and well-tolerated drug (Brewer,
2009). The major side effect is anemia and leukopenia due to
copper depletion, which can be reversed with a drug holiday or
dose reduction.
Additionally, the independent anti-angiogenic effects of the
copper chelator TM present it as a drug that targets both tumor
parenchyma and stroma, by enhancing cisplatin efficacy against
the cancer cells while inhibiting angiogenesis in the tumor micro-
environment. Combination regimens involving copper chelating
and platinum-containing drugs may improve the treatment of
cervical, ovarian, and other cancers for which cisplatin is
currently in use, and for cancers that are treatedwith carboplatin,
whose uptake is also mediated by CTR1 (Holzer et al., 2006).
Such a therapeutic strategy may even prove effective in treating
cancers that are inherently resistant to cisplatin or have devel-
oped resistance. With the development of a second-generation
TM analog that depletes copper more quickly and is more
stable (Lowndes et al., 2008), it may be possible to manipulate
the activity of CTR1 even more effectively. The mechanistic prin-
ciples and results elaborated in this report should motivate
discussion of analogous clinical trials in patients with cervical,
ovarian, and other platinum-responsive cancers.Cancer Cell 17, 574–583, June 15, 2010 ª2010 Elsevier Inc. 581
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Tumor Samples
We obtained ovarian tumor RNA samples from the UCSF Ovarian Cancer
Tissue/Pathology Bank, which has approval from the UCSF Institutional
Review Board to collect ovarian cancer specimens and clinical outcomes
data for research. Written informed consent was obtained from all patients
contributing specimens to the bank. Fifteen samples were available from
women with stage III/IV serous epithelial ovarian carcinoma who underwent
optimal cytoreduction (resulting in residual tumor of 1 cm or less in diameter),
received platinum-based therapy, and had clinical outcome data available.
Tumor samples were snap frozen in liquid nitrogen at the time of surgery
and maintained in a monitored 80C freezer. Adjacent sections were used
for pathology and to confirm that they contained more that 70% tumor cells.
RNA was isolated from snap-frozen tumors using Trizol and its integrity was
determined by Agilent 2100 Bioanalyzer. Responses to initial chemotherapy
were recorded as either refractory/resistant (if there was progression or
recurrence of the disease within 6 months after completion of chemotherapy,
as indicated by an increase in CA-125 levels, a positive finding on CT or
ultrasonography, or second-look laparoscopy) or sensitive (if there was no
such evidence of recurrence within 6 months after completion of chemo-
therapy).
Determination of mRNA Levels with Real-Time PCR
A total of 5 ng cDNA was used for quantitative RT-PCR to measure mRNA
levels of copper transporters in human ovarian tumors and in mouse tissues.
The following TaqMan gene expression assay kits (Applied Biosystems)
were used: Hs00977268_g1 (human Ctr1), Mm00612987_m1 (mouse Ctr1),
Mm00437663_m1 (mouse ATP7A), and Mm00599675_m1 (mouse ATP7B).
The human GUS gene, which encodes b-glucuronidase, and the mouse L19
gene were used as internal amplification controls for human and mouse,
respectively.
Mouse Studies
All animal studies were performed in compliance with the UCSF Guide for
the Care and Use of Laboratory Animals and under approved protocols by
the UCSF Institutional Animal Care and Use Committee.
Platinum Measurement
After cisplatin treatment, organs were harvested and 30 mg tissues were
digested in 500 ml lysis buffer (50 mM Tris [pH 8.0], 20 mM NaCl, 1mM EDT
[pH 8.0], 1% SDS) with 2 mg/ml proteinase K at 55C for 16 hr. Digests were
treated with 0.2 mg/ml RNase at 37C for 1 hr, followed by phenol/chloroform
extraction three times. DNA was precipitated with sodium acetate and isopro-
panol, resuspended in 500 ml H2O, and DNA concentration wasmeasured with
a spectrometer. A total of 2 ppb iridium was added to each sample as an
internal control for inductively coupled plasma mass spectrometry (ICP-MS)
analysis. The platinum reading was normalized to DNA concentration. For
measuring cellular platinum, cells were trypsinized, washed with PBS, and
lysed with 1% Triton X-100/ 0.1% SDS on ice for 30 min. Lysates were spun
at top speed in a microcentrifuge at 4C, and the supernatant was used to
determine protein concentration (Bio-Rad). An equal volume of nitric oxide
was added to the supernatant and digested at 75C for 2 hr for ICP-MS
analysis. The platinum reading was normalized to protein concentration.
Plasma Copper Measurements
Plasma was separated from blood using PST tubes with lithium heparin
(BD microtainer) and digested at 75C for 2 hr with an equal volume of nitric
oxide. A total of 100 ppb cobalt was added to each sample as an internal
control for ICP-MS analysis.
Immunohistochemistry
Optimal cutting temperature (OCT)-embedded frozen tissues were sectioned
at 10 mm thickness. Sections were air-dried, acetone treated, and blockedwith
5%BSA and 2.5% goat serum. Primary antibodies were applied at a dilution of
1:100 for anti-CTR1 and 1:200 for meca-32. Secondary antibodies were used
at 1:500.582 Cancer Cell 17, 574–583, June 15, 2010 ª2010 Elsevier Inc.Western Blotting
Membrane protein extracts were prepared as described (Nose et al., 2006).
Protein concentrations were measured with the BioRad Protein DC Assay
Kit. 5 mg of membrane extracts from tissues were pooled from three mice
and applied on each well. Anti-CTR1 antibody was used at 1:1000. Peroxi-
dase-conjugated goat anti-rabbit immunoglobin G (Jackson Immuno-
Research Laboratories) was used as secondary antibodies at 1:10,000. For
detection, Amersham ECL Western Blotting Reagents were used.
Measurement of Tumor Volume
OCT-embedded cervices were serially sectioned at 10 mm thickness and
stained with hematoxylin and eosin (H&E) every 100 mm. Areas of squamous
cell carcinoma on H&E-stained sections were measured using an Axio
Imager program. Tumor volume (V) was calculated using the following formula
V = 2/33 A3 Z, where A is themaximal tumor areameasured on a section and
Z is the depth of tumor determined by the number of sections containing
tumors.
Tissue Culture
SiHa, A2780, SKOV3, and OVCA4 cells were cultured in RPMI medium
containing 10% fetal bovine serum and penicillin/streptomycin. Ctr1 +/+
(wild-type) and/mouse embryonic fibroblasts were cultured in DMEM sup-
plemented with 20% fetal bovine serum, 2 mM glutamine, 1x nonessential
amino acids, 55 mM 2-mercaptoethanol, 50 mg/L uridine, 110 mg/L pyruvate,
and penicillin/streptomycin. For determining survival, cells were stained with
trypan blue to detect dead cells; unstained cells were counted using a hemo-
cytometer.
Statistics
Wilcoxon analyses were performed to determine two-tailed p values. For
Kaplan-Meier survival estimates, p values were determined from a log-rank
statistic with one degree of freedom.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at doi:10.1016/j.ccr.2010.04.011.
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